SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that a poster featuring preclinical data related to Five Prime’s CSF-1R antibody, cabiralizumab (FPA008), was presented today at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. The poster titled “Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models” is available at http://www.fiveprime.com/news-media/publications-presentations.
“These preclinical findings suggest that the surrogate antibody for FPA008 significantly reduces tumor growth in murine syngeneic tumor models when administered alone and when administered in combination with a PD-1 antibody,” said Kevin Baker, Ph.D., Senior Vice President of Development Sciences at Five Prime. “These findings support previous preclinical data that served as the basis for our Phase 1a/1b clinical trial that we are running in collaboration with Bristol-Myers Squibb (BMS) to investigate the use of cabiralizumab in combination with nivolumab (anti-PD-1, OPDIVO®) in six different tumor types.”
The colony stimulating factor 1 receptor (CSF-1R) signaling pathway promotes tumor progression via the recruitment, differentiation, and survival of immuno-suppressive, M2 polarized, tumor-associated macrophages (TAMs). Five Prime has developed cabiralizumab (FPA008), an IgG4 antibody against CSF-1R that blocks the ability of both CSF-1 and IL-34 to bind and activate this receptor, thereby modulating the immune response to tumorigenesis.
Five Prime has identified alterations in the tumor microenvironment that occur upon CSF-1R inhibition, including significant reduction of immunosuppressive M2 TAMs and an increase in tumor PD-L1 expression. Notably, when dosing in combination, the blockade of CSF-1R and PD-1/PD-L1 results in a significant increase in CD8+ T cells within the tumor. The results show that, when added to PD-1/PD-L1 blockade, the surrogate antibody for FPA008 can significantly enhance anti-tumor efficacy.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.